| Miranda, Robert |
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention |
|
|
| Terminated | 2/3 | 538 | US | BHV-3500 (zavegepant), Placebo | Pfizer | Migraine | 03/24 | 03/24 | | |
NCT04565288: Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine |
|
|
| Completed | 2 | 42 | US | Atomoxetine, Strattera, Placebo | Brown University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 05/23 | 05/23 | | |
NCT04770493: Enhancing the Effects of Alcohol Treatment With Lamotrigine |
|
|
| Completed | 2 | 44 | US | Lamotrigine, Lamictal, Placebo | Brown University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), Rhode Island Hospital | Alcohol Use Disorder | 10/23 | 10/24 | | |
NCT05355311: Enhancing the Effects of Alcohol Treatment With L-Carnitine |
|
|
| Recruiting | 1 | 50 | US | L-carnitine | Brown University, Rhode Island Hospital, Colorado State University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 12/24 | 12/24 | | |
| Isaacson, Stuart |
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale |
|
|
| Terminated | 3 | 7 | Europe, US | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 07/23 | 07/23 | | |
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
| Completed | 3 | 507 | Europe, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 01/24 | 02/24 | | |
| Completed | 3 | 522 | Europe, Canada, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 06/24 | 06/24 | | |
| Terminated | 3 | 1125 | Canada, US, RoW | Simufilam, PTI-125, Placebo | Cassava Sciences, Inc., Premier Research Group plc | Alzheimer Disease | 12/24 | 12/24 | | |
| Active, not recruiting | 2/3 | 110 | Europe, US | AMX0035, Placebo | Amylyx Pharmaceuticals Inc. | Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism | 04/26 | 11/29 | | |
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 |
|
|
| Terminated | 2 | 513 | Europe, US, RoW | K0706, placebo | Sun Pharma Advanced Research Company Limited | Early Parkinson Disease | 04/24 | 06/24 | | |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies |
|
|
| Completed | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia with Lewy Bodies | 11/24 | 11/24 | | |
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424 |
|
|
| Active, not recruiting | 2 | 62 | US | CVN424 150 mg, Placebo | Cerevance Beta, Inc. | Parkinson's Disease | 10/24 | 02/25 | | |
LRRK2-PD, NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease |
|
|
| Recruiting | 2 | 50 | US | BIIB122 225 mg, DNL151, BIIB122-Matching Placebo | Denali Therapeutics Inc., Biogen | Parkinson Disease | 04/26 | 02/28 | | |
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 |
|
|
| Recruiting | 2 | 640 | Europe, Canada, Japan, US, RoW | BIIB122, DNL151, BIIB122-Matching Placebo | Biogen, Denali Therapeutics Inc. | Parkinson Disease | 12/25 | 12/25 | | |
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy |
|
|
| Recruiting | 2 | 80 | US | ONO-2808, Placebo | Ono Pharmaceutical Co. Ltd | Multiple System Atrophy (MSA) | 08/25 | 08/25 | | |
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD |
|
|
| Active, not recruiting | 2 | 237 | Europe, Canada, US | BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo | Bial R&D Investments, S.A. | Parkinson's Disease | 03/26 | 07/26 | | |
| Recruiting | 1 | 9 | US | AAV2-GDNF gene therapy, Sham (Placebo) Surgery | Brain Neurotherapy Bio, Inc. | Multiple System Atrophy | 12/25 | 12/28 | | |
| Active, not recruiting | N/A | 82 | US | | Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals | Parkinson Disease | 02/26 | 02/26 | | |
TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor |
|
|
| Active, not recruiting | N/A | 126 | US, RoW | Felix NeuroAI Wristband, Sham Device | Fasikl Inc. | Essential Tremor | 11/24 | 11/25 | | |
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry |
|
|
| Recruiting | N/A | 25000 | Canada, US, RoW | Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group | Parkinson's Disease | 12/24 | 06/25 | | |
NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy |
|
|
| Active, not recruiting | N/A | 150 | Europe, US | This is an observational study. | Asklepios Biopharmaceutical, Inc. | Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy | 08/25 | 10/25 | | |
| Active, not recruiting | N/A | 25000 | Europe, Canada, US, RoW | | CENTOGENE GmbH Rostock | Parkinson´s Disease | 12/25 | 12/25 | | |
| Recruiting | N/A | 4500 | Europe, Canada, US, RoW | | Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders | Parkinson Disease | 12/33 | 12/33 | | |
| Mari, Zoltan |
| Completed | 3 | 507 | Europe, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 01/24 | 02/24 | | |
| Completed | 3 | 522 | Europe, Canada, US, RoW | Tavapadon, PF-06649751, CVL-751, Placebo | Cerevel Therapeutics, LLC | Parkinson Disease | 06/24 | 06/24 | | |
NCT05251701: Personal KinetiGraph® Clinical Validation Study |
|
|
| Recruiting | N/A | 500 | US | Personal KinetiGraph® (PKG®) System | Global Kinetics Corporation | Movement Disorders, Parkinson Disease | 01/24 | 01/25 | | |
| Active, not recruiting | N/A | 82 | US | | Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals | Parkinson Disease | 02/26 | 02/26 | | |
| Recruiting | N/A | 4500 | Europe, Canada, US, RoW | | Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders | Parkinson Disease | 12/33 | 12/33 | | |
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort |
|
|
| Recruiting | N/A | 35000 | Europe, Canada, US, RoW | | CHDI Foundation, Inc. | Huntington's Disease | 01/62 | 01/62 | | |
| Benenati, Diana |
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes |
|
|
| Terminated | 2 | 8 | US | Apomorphine Cartridge, placebo | Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc. | Parkinson Disease | 02/24 | 02/24 | | |
NCT05251701: Personal KinetiGraph® Clinical Validation Study |
|
|
| Recruiting | N/A | 500 | US | Personal KinetiGraph® (PKG®) System | Global Kinetics Corporation | Movement Disorders, Parkinson Disease | 01/24 | 01/25 | | |
| Mutterperl, Robert |
| Completed | 3 | 4223 | Europe, US | ABNCoV2, Comirnaty | Bavarian Nordic | COVID-19 Disease | 03/23 | 10/23 | | |
NCT05925127: Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines |
|
|
| Completed | 2/3 | 994 | US | NVX-CoV2373 (5μg), NVX-CoV2601 (5μg), Omicron XBB.1.5, NVX-CoV2601(5μg), NVX-CoV2601 (35μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5, Omicron Subvariant/Prototype Licensed mRNA Vaccine | Novavax | COVID-19 | 05/24 | 05/24 | | |
NCT05288504: A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma. |
|
|
| Completed | 2 | 91 | US | AVTX-002, CERC-002, AEVI-002, MDGN-002, Placebo | Avalo Therapeutics, Inc. | Non-Eosinophilic Asthma | 05/23 | 05/23 | | |
